Röllig, C., Steffen, B., Schliemann, C., Mikesch, J., Alakel, N., Herbst, R., Hänel, M., Noppeney, R., Hanoun, M., Kaufmann, M., Weinbergerova, B., Schäfer-Eckart, K., Sauer, T., Neubauer, A., Burchert, A., Baldus, C. D., Mertová, J., Jost, E., Niemann, D., Novak, J., Krause, S. W., Scholl, S., Hochhaus, A., Held, G., Szotkowski, T., Rank, A., Schmid, C., Fransecky, L., Kayser, S., Schaich, M., Krämer, M., Fiebig, F., Haake, A., Schetelig, J., Middeke, J. M., Stölzel, F., Platzbecker, U., Thiede, C., Müller-Tidow, C., Berdel, W. E., Ehninger, G., Mayer, J., Serve, H., Bornhäuser, M. (2025). Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00235